Recon: Pfizer to buy $500M of stock in smaller drugmakers; India approves remdesivir for emergency use

• Internal FDA Documents Show How Little Evidence The Agency Had Before Allowing Malaria Drugs To Be Used To Treat COVID-19 (BuzzFeed)
• Only 891 in Free HIV-Prevention Drug Program Meant for 200,000 (Bloomberg)
• Pfizer to invest up to $500 million in public drug developers (Reuters) (STAT) (Endpoints)
• White House Coronavirus Testing Czar To Stand Down (NPR)
• Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions (Reuters)
• Operation Warp Speed selects billionaire scientist’s COVID-19 vaccine for monkey tests (Science)
• Bristol Myers' treatment succeeds in late-stage bowel disease study (Reuters) (Endpoints)
• New US approval for AZ' Brilinta (PharmaTimes)
• Amneal recalls metformin due to NDMA impurity (FDA)
• ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress (STAT)

• WHO and other experts say no evidence of coronavirus losing potency (Reuters)
• India approves emergency use of remdesivir to treat COVID-19 patients (Reuters)
• CDSCO faces CIC ire over ‘misplaced’ 2013 report on ‘irregular’ approval to drugs (Indian Express)
• First results from UK's Recovery COVID-19 drug trial expected in early July (Reuters)
• The 20 executives — and companies — to know in Chinese biotech (STAT)
• Japan allows saliva-based tests to boost coronavirus detection (Reuters)
• Novacyt shares drop as France refuses to refund virus test (Reuters)
• South Korea expects human trials of Celltrion's potential COVID-19 treatment in Europe (Reuters)
• EU Health Program To Help Boost Post-Coronavirus Recovery (Pink Sheet)

• US and Chinese Scientists Trace Evolution of Coronaviruses in Bats (NYTimes)
• Nearly 26,000 Nursing Home Residents Have Died From COVID-19, Federal Data Show (NPR)
• Why Merck waited, and what they now bring to the Covid-19 fight (Endpoints)
• Medical Workers Should Use Respirator Masks, Not Surgical Masks (NYTimes)
• No new COVID sufferers, 300 asymptomatic, after Wuhan-wide tests (Reuters)
• Coronavirus (COVID-19) Update: Daily Roundup June 1, 2020 (FDA)

• Life After Woodcock: US FDA Drug Center’s Leadership Transition (Pink Sheet)
• Pfizer’s Zoloft Falls Into Shortage as Virus Strains Supplies (Bloomberg)
• For COVID, Consensus On Value Of Platform Trials, But A Confusion Of Consortia (Pink Sheet)
• ASCO: Momentum gathers behind next wave of CAR-T therapies (PMLive)
• Gilead woos filgotinib clinical investigator from Stanford to lead the charge on NASH, inflammatory diseases (Endpoints)
• 15 Drug Makers See 3.6% Negative Growth in Japan in FY2020 as Re-Pricing, Generic Entries Weigh: Jiho Tally (PharmaJapan)
• Spark touts animal data for a solution to AAV gene therapy's antibody problem (Endpoints)
• AbbVie files Rinvoq for psoriatic arthritis (PharmaTimes)
• Regeneron expands Intellia gene editing deal as its post-Sanofi future emerges (BioPharmaDive)
• Opinion: It’s time to bring generic drug manufacturing back to the US (STAT)
• Opinion: Covid-19 has exposed cracks in the global medicines supply chain. We need to fix them (STAT)
• Novartis chips in $10M for IPO-bound partner Pliant; Tenax shares soar on heart drug data (Endpoints)
• Once a high flyer, a staggering Aduro is auctioning off most of the pipeline as CEO Stephen Isaacs hands off the shell to new owners (Endpoints)
• Hillhouse recasts spotlight on China's biotech scene with $160M round for Shanghai-based antibody maker (Endpoints)
• Novus Therapeutics plunges deep into penny stock territory after failed ear trial (Endpoints)

• Many heart device trials 'small and fragile,' come with misleading spin: JAMA study (MedtechDive)
• Tests to detect cancer, guide treatment heat up with barrage of data at ASCO (MedtechDive)
• The FDA Requests Allergan Voluntarily Recall Natrelle BIOCELL Textured Breast Implants and Tissue Expanders from the Market to Protect Patients: FDA Safety Communication (FDA)
• FDA alerts patients and health care professionals of Amneal and Impax Laboratories epinephrine auto-injector device malfunctions (FDA)

• Debate over hydroxychloroquine spills over from the White House to congressional campaigns (STAT)
• EPA Finalizes Ethylene Oxide Reduction To Lower Cancer Risk (Law360)
• Immunomedics Must Face Suit Over Drug Presentation Claims (Law360)
• Further changes to reduce opioid harm (TGA)
• Submissions received: Proposed clarification of the regulatory requirements for medical device systems or procedure packs (TGA)